First Report of National Consensus Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Iran
- 16 May 2026
- journal article
- practice guideline
- Published by Wiley in Helicobacter
- Vol. 31 (3) , e70137
Abstract
Background: Helicobacter pylori infection remains a major public health concern in Iran, where high prevalence, alarming antibiotic resistance, and significant gastric cancer burden necessitate a unified and evidence‐based national strategy. Despite the availability of international guidelines, gaps in clinical practice persist due to local epidemiology, resistance patterns, and diagnostic challenges. This study presents the first national Iranian consensus guideline for the diagnosis and management of H. pylori infection. Methods: A multidisciplinary panel of experts from leading Iranian gastroenterology centers convened between August 2023 and October 2025. Using the GRADE framework, the scientific committee conducted systematic literature reviews and formulated evidence‐based statements across diagnostic, therapeutic, and clinical management domains. Consensus was defined as ≥ 80% agreement. Twelve structured meetings, including a final hybrid national consensus conference, were held to refine recommendations. Results: The guideline delivers 35 evidence‐graded statements addressing indications for testing and treatment, optimal diagnostic modalities, and treatment pathways. Key recommendations include a strong preference for non‐invasive testing in patients under 45 without alarm features, endoscopic evaluation with targeted biopsies in high‐risk groups, and confirmation of eradication using urea breath test (UBT) or monoclonal stool antigen test (SAT) at ≥ 4 weeks post‐treatment. Given Iran's high clarithromycin resistance (> 20%), a course of 10–14 days bismuth quadruple therapy (BQT) is recommended as first‐line treatment, with non‐bismuth concomitant therapy as an alternative. Susceptibility‐guided therapy is encouraged when feasible, particularly after treatment failure. High‐dose proton pump inhibitor (PPI) or potassium competitive acid blocker (P‐CAB)‐based acid suppression is emphasized to enhance eradication efficacy. Special considerations are provided for renal/hepatic impairment and drug interactions. Conclusion: This national guideline provides a standardized, evidence‐based framework for improving H. pylori diagnosis and management. By integrating local antimicrobial resistance patterns and practical clinical considerations, the guideline helps optimize eradication rates, reinforce antibiotic stewardship, and contribute to gastric cancer prevention efforts across Iran.Keywords
This publication has 118 references indexed in Scilit:
- Helicobacter pylori infection contributes to the expression of Alzheimer's disease-associated risk factors and neuroinflammationHeliyon, 2023
- Diagnostic methods for Helicobacter pylori infection: ideals, options, and limitationsEuropean Journal of Clinical Microbiology & Infectious Diseases, 2018
- Potent Acid Suppression with PPIs and P-CABs: What’s New?Current Treatment Options in Gastroenterology, 2018
- Hematological parameters, serum iron and vitamin B 12 levels in hospitalized Palestinian adult patients infected with Helicobacter pylori : a case–control studyHematology, Transfusion and Cell Therapy, 2018
- The use of stool specimens reveals Helicobacter pylori strain diversity in a cohort of adolescents and their family members in a developed countryInternational Journal of Medical Microbiology, 2017
- Eradication of Helicobacter pylori InfectionCurrent Gastroenterology Reports, 2016
- Biopsies in Gastrointestinal Endoscopy: When and HowGE - Portuguese Journal of Gastroenterology, 2016
- Pharmacologic Aspects of Eradication Therapy for Helicobacter pylori InfectionGastroenterology Clinics of North America, 2010
- Pharmacokinetics and Pharmacodynamics of Antibacterial AgentsInfectious Disease Clinics of North America, 2009
- Antibody-Independent Protective Mucosal Immunity to Gastric Helicobacter Infection in MiceCellular Immunology, 1999